======= SARS ======= == Gene Information == * **Official Symbol**: SARS1 * **Official Name**: seryl-tRNA synthetase 1 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=6301|6301]] * **UniProt**: [[https://www.uniprot.org/uniprot/P49591|P49591]] * **Interactions**: [[https://thebiogrid.org/search.php?search=SARS&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20SARS|Open PubMed]] * **OMIM**: [[https://omim.org/entry/607529|Open OMIM]] == Function Summary == * **Entrez Summary**: N/A * **UniProt Summary**: Catalyzes the attachment of serine to tRNA(Ser) in a two-step reaction: serine is first activated by ATP to form Ser- AMP and then transferred to the acceptor end of tRNA(Ser) (PubMed:22353712, PubMed:24095058, PubMed:9431993, PubMed:26433229, PubMed:28236339). Is probably also able to aminoacylate tRNA(Sec) with serine, to form the misacylated tRNA L-seryl-tRNA(Sec), which will be further converted into selenocysteinyl-tRNA(Sec) (PubMed:9431993, PubMed:26433229, PubMed:28236339). In the nucleus, binds to the VEGFA core promoter and prevents MYC binding and transcriptional activation by MYC (PubMed:24940000). Recruits SIRT2 to the VEGFA promoter, promoting deacetylation of histone H4 at 'Lys-16' (H4K16). Thereby, inhibits the production of VEGFA and sprouting angiogenesis mediated by VEGFA (PubMed:19423848, PubMed:19423847, PubMed:24940000). {ECO:0000269|PubMed:19423847, ECO:0000269|PubMed:19423848, ECO:0000269|PubMed:22353712, ECO:0000269|PubMed:24095058, ECO:0000269|PubMed:24940000, ECO:0000269|PubMed:26433229, ECO:0000269|PubMed:28236339, ECO:0000269|PubMed:9431993}. |tRNA-synt 2b| |Seryl tRNA N| |seryl-tRNA aminoacylation| |serine-tRNA ligase activity| |negative regulation of vascular endothelial growth factor production| |selenocysteinyl-tRNA(Sec) biosynthetic process| |selenocysteine metabolic process| |regulation of vascular endothelial growth factor production| |serine family amino acid metabolic process| |tRNA aminoacylation for protein translation| |tRNA aminoacylation| |amino acid activation| |negative regulation of angiogenesis| |negative regulation of blood vessel morphogenesis| |negative regulation of vasculature development| |tRNA processing| |tRNA metabolic process| |alpha-amino acid metabolic process| |negative regulation of cytokine production| |regulation of angiogenesis| |cellular amino acid metabolic process| |regulation of vasculature development| |translation| |ncRNA processing| |peptide biosynthetic process| |ncRNA metabolic process| |RNA polymerase II proximal promoter sequence-specific DNA binding| |amide biosynthetic process| |peptide metabolic process| |RNA biosynthetic process| |regulation of cytokine production| |cellular amide metabolic process| |negative regulation of transcription by RNA polymerase II| |RNA processing| |protein homodimerization activity| |carboxylic acid metabolic process| |negative regulation of developmental process| |oxoacid metabolic process| |organic acid metabolic process| |regulation of anatomical structure morphogenesis| |nucleobase-containing compound biosynthetic process| |heterocycle biosynthetic process| |aromatic compound biosynthetic process| |negative regulation of transcription, DNA-templated| |negative regulation of multicellular organismal process| |negative regulation of nucleic acid-templated transcription| |negative regulation of RNA biosynthetic process| |organic cyclic compound biosynthetic process| |negative regulation of RNA metabolic process| |negative regulation of cellular macromolecule biosynthetic process| |RNA binding| |organonitrogen compound biosynthetic process| |negative regulation of nucleobase-containing compound metabolic process| |negative regulation of macromolecule biosynthetic process| |ATP binding| |negative regulation of cellular biosynthetic process| |negative regulation of biosynthetic process| |cellular nitrogen compound biosynthetic process| |RNA metabolic process| |cellular macromolecule biosynthetic process| |negative regulation of gene expression| |small molecule metabolic process| |macromolecule biosynthetic process| |gene expression| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp497|Lead acetate 2000μM R08 exp497]]|-2.83| |[[:results:exp467|CAY10603 0.55μM R08 exp467]]|-2.73| |[[:results:exp407|Thapsigargin 0.005μM R07 exp407]]|-2.6| |[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|-2.49| |[[:results:exp65|Mubritinib 0.2μM R02 exp65]]|-2.4| |[[:results:exp330|5-Azacytidine 2μM R07 exp330]]|-2.28| |[[:results:exp133|MKC9989 10μM R03 exp133]]|-2.24| |[[:results:exp93|DABN racemic mixture R03 exp93]]|-2.21| |[[:results:exp520|Rucaparib 6.5μM R08 exp520]]|-2.18| |[[:results:exp357|Dorsomorphin 5μM R07 exp357]]|-2.17| |[[:results:exp473|Cincreasin 100μM R08 exp473]]|-2.15| |[[:results:exp505|ML-792 0.2μM R08 exp505]]|-2.11| |[[:results:exp352|Dexamethasone 0.006 to 0.015μM on day4 R07 exp352]]|-2.07| |[[:results:exp45|Docetaxel 0.002μM R01 exp45]]|-2.05| |[[:results:exp485|GSK626616 14μM R08 exp485]]|-2.02| |[[:results:exp431|Rotenone 0.07μM R08 exp431]]|-2| |[[:results:exp476|Dihydrosphingosine 8μM R08 exp476]]|-1.98| |[[:results:exp512|Olaparib 4μM R08 exp512]]|-1.88| |[[:results:exp142|OICR-9429 10μM R03 exp142]]|-1.72| |[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|-1.71| |[[:results:exp7|Bortezomib 0.05μM R00 exp7]]|1.73| |[[:results:exp472|CI-1040 9.5μM R08 exp472]]|1.78| |[[:results:exp401|SNS-032 25μM R07 exp401]]|1.78| |[[:results:exp531|THZ1 0.06μM R08 exp531]]|1.8| |[[:results:exp526|Sulforaphane 9μM R08 exp526 no dilution day6]]|1.82| |[[:results:exp456|Benzoate 20000μM R08 exp456]]|2.06| |[[:results:exp451|Atovaquone 15μM R08 exp451]]|2.09| |[[:results:exp493|IL-3 9ng/ml R08 exp493]]|2.11| |[[:results:exp19|Etoposide 1μM R00 exp19]]|2.13| |[[:results:exp465|Cannabidiol 13μM R08 exp465]]|2.74| |[[:results:exp469|CFI-400945 25μM R08 exp469]]|2.81| |[[:results:exp514|Phorbol-12-myristate-13-acetate 0.57μM R08 exp514]]|2.81| ^Gene^Correlation^ |[[:human genes:h:hars|HARS]]|0.497| Global Fraction of Cell Lines Where Essential: 739/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|1/1| |909776.0|1/1| |bile duct|28/28| |blood|28/28| |bone|26/26| |breast|33/33| |central nervous system|56/56| |cervix|4/4| |colorectal|17/17| |esophagus|13/13| |fibroblast|1/1| |gastric|16/16| |kidney|21/21| |liver|20/20| |lung|75/75| |lymphocyte|16/16| |ovary|26/26| |pancreas|24/24| |peripheral nervous system|16/16| |plasma cell|15/15| |prostate|1/1| |skin|24/24| |soft tissue|9/9| |thyroid|2/2| |upper aerodigestive|22/22| |urinary tract|29/29| |uterus|5/5| == Essentiality in NALM6 == * **Essentiality Rank**: 170 * **Expression level (log2 read counts)**: 7.15 {{:chemogenomics:nalm6 dist.png?nolink |}}